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Spray drying and pulmonary administration.Sss
A B S T R A C T
Worldwide resurgence of whooping cough calls for improved, next-generation pertussis vaccines that induce
broad and long-lasting immunity. A mucosal pertussis vaccine based on outer membrane vesicles (omvPV) is a
promising candidate. Further, a vaccine that is stable outside the cold chain would be of substantial advantage
for worldwide distribution and application. A vaccine formulated as a powder could both stabilize the vaccine as
well as make it suitable for pulmonary vaccination. To that end, we developed a spray dried omvPV with
improved stability compared to the liquid omvPV formulation. Spray drying did not affect the structural in-
tegrity of the omvPV. The antigenicity of Vag8, a major antigen in omvPV was diminished slightly and an altered
tryptophan fluorescence indicated some changes in protein structure. However, when administered via the
pulmonary route in mice after reconstitution, spray dried omvPV showed comparable immune responses and
protection against challenge with live B. pertussis as liquid omvPV. Mucosal IgA and Th17 responses were es-
tablished in addition to broad systemic IgG and Th1/Th17 responses, indicating the induction of an effective
immunity profile. Overall, a spray dried omvPV was developed that maintained effective immunogenic prop-
erties and has an improved storage stability.
1. Introduction
Pertussis or whooping cough, caused by the gram-negative bacteria
Bordetella pertussis, is a highly contagious airway infection. Young,
unvaccinated infants represent the most vulnerable group with the
highest rate of respiratory complication and death following B. pertussis
infection [1, 2]. Immunization against whooping cough is recognized as
a cost-effective method for controlling the disease. Currently two types
of pertussis vaccines are used in vaccination programs: whole-cell in-
activated pertussis vaccine (wPV) and acellular pertussis vaccine (aPV)
[3, 4]. However, the recent resurgence of whooping cough due to strain
adaptation and waning immunity, has brought the efficacy of current
vaccines under scrutiny [5, 6]. Therefore, the call for improved per-
tussis vaccines remains pertinent.
A novel pertussis vaccine based on outer membrane vesicles
(omvPV) is a potential vaccine candidate. OMVs are naturally produced
by B. pertussis [7, 8] and consist of a broad range of immunogenic
antigens in their native conformation [9, 10]. After subcutaneous im-
munization, omvPV protects mice to a comparable degree as aPV and
wPV, based on lung colonization data obtained after B. pertussis chal-
lenge [9, 11, 12]. Moreover, omvPV elicited a broader humoral im-
munity against more antigens as well as more different antibody sub-
types compared to aPV [10] and mixed systemic T-helper 1, 2 and 17
responses [12–14], which are also found in responses to a B. pertussis
infection [13, 15, 16]. Importantly, we recently demonstrated that
administration of omvPV at mucosal membranes, the port of entry for
B. pertussis, conferred superior immunity over subcutaneous adminis-
tration. The response was characterized by induction of mucosal IgA,
and improved B-cell and Th17 responses [13].
Maintenance of the cold chain is challenging and complicating for
the widespread vaccine distribution, especially in developing countries
[17, 18]. During cold chain transport, accidental exposure to higher or
freezing temperatures could occur, which can be detrimental for the
potency of traditional vaccines [18]. The cold chain also adds up to the
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financial burden of the vaccination programs. A future pertussis vaccine
should therefore not only be more effective, but ideally also stable at
tropical temperatures and affordable.
A way to stabilize vaccines is to spray dry them in the presence of
stabilizing excipients. Removal of water and incorporation of excipients
can improve the vaccine stability due to decreased mobility and pre-
vention of degradation pathways that are facilitated by water [19].
Unlike lyophilization, the potential damage to antigens caused by
freezing is avoided when spray dried. In addition, the spray drying
process is fast (taking only several minutes) and consumes less energy
compared to freeze-drying (which can take several days). Faster drying
will result in lower operating costs. Previous studies have indicated the
potential of spray dried vaccines to overcome requirements for cold
chain, as they possess a longer shelf life at elevated temperatures
[20–24]. The edge of spray drying resides in its ability for dry particles
to be engineered to desired requirements [25–27], which can be used
for pulmonary, intranasal or oral delivery [28–33]. To the best of our
knowledge, no spray dried formulation of omvPV has been developed
so far.
The purpose of this study was to design a dry powder formulation of
omvPV with extended storage stability. Firstly, we formulated a spray
dried omvPV using trehalose as a stabilizer. Besides physical char-
acteristics of the powder, we investigated the preservation of the
structural integrity and biological activity of a spray dried omvPV in
comparison to the (non-processed) liquid omvPV formulation.
Secondly, a stability study was performed by storage of spray dried
omvPV at elevated temperatures (4 weeks at 40 °C and 65 °C). Finally,
the effects of drying on the immunogenicity were tested in an in vivo
model in which mice were pulmonary immunized with reconstituted
spray dried omvPV or with subcutaneous liquid omvPV that resembles
the conventional route of intramuscular administration for pertussis
vaccines in humans. The induction of protective immunity markers
such as antibody, B-cell and T-cell responses next to the protection ef-
ficacy after intranasal B. pertussis challenge were compared.
2. Materials and methods
2.1. Materials
The excipient D-(+) trehalose dihydrate was purchased from Sigma
(USA) and PBS (0.01M, pH 7.2) from Gibco life technology (USA).
2.2. Vaccine and antigens
The omvPV from B. pertussis B1917 was produced as previously
described [12]. Pertussis monoclonal antibodies directed towards
Virulence associated gene 8 (Vag8) and Pertactin (Prn) were kindly
provided by the Dutch National Institute for Public Health and the
Environment (Bilthoven, the Netherlands).
2.3. Formulation preparation
For spray drying, 2mL omvPV stock solution (890 μg/mL total
protein) was mixed with 18mL D-(+)-trehalose dihydrate (100mg/
mL) solution in PBS (matrix) to a final volume of 20mL (89 μg/mL total
protein concentration). The trehalose solution was filtered using a
0.45mm Millex-HV filter (Millipore) prior to mixing with the vaccine.
2.4. Spray drying process
The spray dried omvPV was produced using a Büchi mini spray-
drier B-290 in conjunction with a high performance cyclone and a B-
296 dehumidifier (both from Büchi Labortechnik AG). All the experi-
ments were performed in a closed loop configuration using nitrogen as
drying medium. A two-way nozzle with orifice diameter of 0.7mm was
used in a co-current mode with nitrogen as atomizing gas. The nitrogen
pressure was set constant at 5 bar. The spray drying parameters were
adapted from a study described previously [20]. The inlet air tem-
perature was set at 135 °C. The feed flow rate is displayed in percentage
(%) on the equipment and feed flow rate of 10% corresponding to
3.4 mL/min. An atomizing airflow of 12.4 L/min. The aspirator rates
were set at 22m3/h in all experiments.
After spray drying, the spray dried product was collected, aliquoted
(100mg) in vials (3mL vial, Nuova Ompi) in a N2-flushed glove box
(Terra Universal Inc., Series 100) at a relative humidity of< 3% and
sealed. The powder yield was determined as described previously [20].
2.5. Thermostability study
The sealed spray dried (100mg per vial) and liquid omvPV (100 μL
per vial) were stored for 4 weeks at 40 °C and 65 °C. Samples were
collected at day 0 (after drying), 1, 7, 15 and 30 (after storage) for
further analysis.
2.6. Geometric particle size
The particle size of the spray dried powder product was analyzed by
laser diffraction with a Helos system (Sympatec GmbH) and distribution
data of the spray dried product was reported as cumulative undersize
distribution. The particle sizes at its undersize values of 10%, 50% and
90% (denoted as X10, X50 and X90 respectively). The geometric particle
size (X50 defined as the median particle size). The powder was dispersed
into the Helos system using an Aspiros dispersing system operated at a
dispersing pressure of 1.0 bar. The vaccine powder was measured with
a lens having a measuring range of 0.1/0.18–35mm. Furthermore, to
check for any aggregates, the analysis was repeated by increasing the
dispersing pressure (between 1 and 5 bar). Results are presented as the
mean of three measurements.
2.7. Scanning electron microscopy (SEM)
The morphology of the particles was visualized using a JSM 6301F
scanning electron microscope (JEOL). Spray dried omvPV samples were
prepared by placing the powders on double-sided sticky carbon tape on
a metal disk. Subsequently, the particles were coated with a gold layer
with a thickness of approximately 10 nm using a Balzers 120 B sput-
tering device (Balzer UNION). The voltage used for the analysis was
10 kV with a spot size of 7–8. Images were taken at a magnification of
1000× and 5000×.
2.8. Cryo-Transmission Electron Microscopy (Cryo-TEM)
A few microliters of sample was deposited on a holey carbon-coated
copper grid (Quantifoil 3.5/1). After blotting the excess of the sample
with filter paper, the grids were plunged into liquid ethane (FEI vi-
trobot). Frozen-hydrated specimens were mounted in a cryo-stage
(Gatan, model 626) and observed in a FEI Tecnai T20 electron micro-
scope, operating at 200 kV. Micrographs were recorded under low-dose
conditions on a slow-scan CCD camera (Gatan, model 794).
2.9. Prn and Vag8 antigen ELISA
The reconstituted spray dried omvPV (in PBS) and liquid omvPV
control were coated 100 μL/well (serially diluted between 6 and
0.375 μg/mL), on flat bottomed 96 well plates (Immulon, 2 HB, Fisher
Scientific). The plates were sealed and incubated overnight at room
temperature. The next day, the coating solution was discarded and
washed 6 times with wash buffer (0.05% Tween80 in demineralized
water), plates were blocked with blocking buffer (0.5% Protifar in PBS)
for 30min at 37 °C. Plates were washes 6 times, and subsequently in-
cubated for 1.5 h at 37 °C with specific monoclonal antibodies against
Prn (1:20) or Vag8 (1:50) diluted in reagent buffer (0.1% Tween80 in
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PBS). After washing 6 times, plates were incubated for 1.5 h at 37 °C
with goat-anti-mouse-IgG-HRP (Southern Biotech). Finally, plates were
washed 6 times and TMB substrate (Sigma–Aldrich) solution was
added. The colour reaction was stopped with 2M of H2SO4 (Bilthoven
Biologics) and absorbance was read at OD450 with a Synergy Mx plate
reader (BioTek). The data is represented as total omvPV protein con-
centration vs absorbance. The loss in binding intensity is measured by
calculating the difference in absorbance at different concentrations.
2.10. Residual moisture content (RMC)
The RMC of spray dried omvPV samples was determined using a
C30 Compact Karl Fischer Coulometer (Mettler-Toledo) as previously
described [20].
2.11. Differential scanning calorimetry
Modulated differential scanning calorimetry (mDSC) was conducted
using a TA DSC Q100 (TA instruments) as described previously [20].
2.12. Protein digestion and peptide identification with LC−MS/MS
analysis
Liquid omvPV or reconstituted spray dried omvPV samples were
diluted in a denaturation buffer containing 1M guanidine hydro-
chloride (Sigma) and 50mM triethylammonium bicarbonate (Sigma),
pH 8.5, to a final concentration of 0.2 mg/mL protein. The digestion
was carried out as described previously [10]. Samples were analyzed by
nanoscale reversed-phase liquid chromatography electrospray mass
spectrometry and the analysis was performed on LTQ-Orbitrap XL mass




Liquid omvPV and reconstituted spray dried omvPV containing
80 μg/mL of total protein were analyzed. Spectra (3 averaged scans,
excitation 295 nm, emission 300–450 nm, 50 nm/min and band width
2.5 nm for both excitation and emission) were recorded on a LS55
fluorescence spectrometer (PerkinElmer, USA). All fluorescence spectra
were corrected for matrix background. The measurements were per-
formed in triplicate.
2.13.2. Extrinsic fluorescence
Liquid omvPV and reconstituted spray dried omvPV containing
80 μg/mL of total protein were analyzed. Bis-ANS (Sigma) was dis-
solved in MilliQ water and added to the samples at a final concentration
of 10 μM. Samples were incubated for 20min (dark, room temperature).
Emission spectra (3 averaged scans, 430–600 nm, 50 nm/min) were
recorded using an excitation wavelength of 395 nm (band width
2.5 nm). All spectra were corrected by subtracting the matrix back-
ground. The measurements were performed in triplicate.
2.14. Dynamic light scattering (DLS)
OmvPV particle size was measured using a Zetasizer Nano-ZS
system (Malvern Instruments, UK). DLS measurements were done in
triplicate with 0.1mL liquid vaccine (in matrix) and reconstituted spray
dried powder omvPV at an operating temperature of 25 °C.
Homogeneity of the size distribution was reflected in the polydispersity
index (PdI), which ranges between 0.0 (monodisperse) and 1.0 (random
size distribution).
2.15. Powder X-ray diffractometry (XRD)
Spray dried omvPV samples were analyzed by a D2 Phaser desktop
X-ray diffractometer equipped with a LynxEye Si strip one-dimensional
detector (both from Bruker AXS). The samples were exposed to Cu Kα
(X-rays) at an angular ranging from 5° to 30° 2&z. Theta, with a step
size of 0.01° and a dwell time of 0.5 s. The crystalline status of the
powder was assessed qualitatively by examination of the resulting dif-
fraction patterns.
2.16. Immunization and challenge of mice
Female, 8-week old BALB/c mice (Harlan, The Netherlands) were
immunized twice (day 0 and 28) with 4 μg total protein omvPV either
administered pulmonary (as a liquid; 50 μL), pulmonary (as a recon-
stituted powder; 50 μL), or subcutaneously (as a liquid; 300 μL).
Pulmonary administration was performed using a MicroSprayer aero-
solizer supplied with a high-pressure syringe (IA-1C and FMJ-250;
Penn-Century, Philadelphia, USA), as described previously [13]. The B.
pertussis challenge with 2x10E5 colony forming units (CFU) of strain
B1917 was performed as described previously [34].
2.17. Sample collection
Mice were anesthetized (isoflurane/oxygen) for orbital blood col-
lection and sacrificed at day 56, by cervical dislocation. Serum was
obtained by collecting whole blood in a serum collection tube
(MiniCollect 0.8 mL Z Serum Sep GOLD, Greiner). After coagulation
(10min., room temperature) and centrifugation (10min., 3000 g), sera
were collected, aliquoted and stored at −80 °C. For antibody detection
and colonization assays, the lungs and trachea were homogenized in
THIJS medium [35] using a Bio-Gen PRO200 Homogenizer (Pro Sci-
entific Inc., Oxford, USA) while nose lavages were obtained by flushing
the nose with 1mL THIJS medium. For B- and/or T-cell assays, com-
plete lungs and spleens were collected in RPMI complete medium
[RPMI-1640 medium (Gibco) supplemented with 10% FCS (Hyclone),
100 units penicillin, 100 units streptomycin and 2.92mg/mL L-gluta-
mine (Invitrogen)] and homogenized using a 70-μm cell strainer (BD
Falcon, BD Biosciences). Erythrocytes in spleen and lung samples were
lysed using home-made lysis buffer (10 g/L NH4Cl, 1.25 g/L NaHCO3,
0.125mM EDTA in dH20; pH 7.4). Whole blood for B-cell assays was
collected in heparinized tubes (MiniCollect 1 mL LH, Greiner, Austria)
after which erythrocytes were lysed using RBC lysis buffer (Pharm Lyse,
BD).
2.18. Colonization assays
Lung and trachea lysates, and nose lavages were serially diluted
(undiluted, 1:10, 1:100, and 1:1000) in THIJS medium. Subsequently,
samples were plated on Bordet-Gengou agar plates and incubated for
5 days at 35 °C. The number of CFU/mL was determined using a colony
counter (ProtoCOL, Synbiosis, Cambridge, UK).
2.19. Antibody measurements
Antibodies specific for BrkA (Bordetella resistance to killing), Fim2/
3, Filamentous hemagglutinin (FHA), OMV, Prn, Pertussis toxin (Ptx),
and Vag8 were measured using a previously described mouse multiplex
immunoassay (MIA) [13]. Serum samples were diluted 1:2000 for anti-
OMV IgG and 1:100 for IgG (subclass) and IgA measurements. Lung
lysates and nasal washes were diluted 1:10 and undiluted, respectively,
for measuring IgA levels. Data were acquired with a Bio-Plex 200,
processed using Bio-Plex Manager software (v5.0, Bio-Rad Labora-
tories), and presented as fluorescence intensities (FI).
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2.20. Immunoproteomic profiling
To identify immunogenic proteins in omvPV, SDS-PAGE and
Western blotting was used to analyze pulmonary IgA and serum IgG
antibody responses as described with a little modification [10, 13]. In
this study, nitrocellulose membranes (Thermo Scientific) were used.
Western blotting was used for analysis of the epitope availability of
proteins present in omvPV samples that were included in the stability
study [10]. In short, proteins in the omvPV samples (5 μg/sample) were
separated with SDS-PAGE and blotted on nitrocellulose membranes
(Thermo Scientific). Subsequently, the blots were incubated (1:100
dilution) with an equal mixture of murine sera from three omvPV-im-
munized groups (pulmonary liquid, pulmonary reconstituted powder
and subcutaneous liquid) derived from the animal experiment used in
this study that was described earlier.
2.21. B-cell ELISpot
Analysis of OMV-specific IgG- and IgA-producing plasma cells in
blood, spleen and lungs and analysis of OMV-specific memory B-cells in
spleen and lungs were determined by ELISpot, as described before [13].
Plates were coated with 10 μg/mL wildtype B1917 OMV.
2.22. Multiplex cytokine analysis
The concentration of T-helper subset cytokines (IL-4, IL-5, IL-10, IL-
13, IL-17A, TNFα and IFNγ) was determined in splenic culture super-
natant using a ProcartaPlex Mix&Match Mouse 7-plex (Thermo-Fisher).
Data acquisition and analysis were executed with a Bio-Plex 200 (Bio-
Rad) and using Bio-Plex Manager software (v5.0, Bio-Rad). Results
were corrected for the background (IMDM complete medium control)
per mouse per stimulation per cytokine, and calculated in pg/mL.
2.23. Statistics
Significance of differences between spray dried and liquid omvPV in
the Prn and Vag8 ELISA were determined using a 2-way ANOVA.
Significance of inter-group differences for B-cell ELISpot analysis was
determined using a Mann-Whitney t-test. Data from antibody, cytokine,
and colonization assays were log-transformed and statistically tested
using a t-test. P-values ≤0.05 were considered as significant differ-
ences.
3. Results
3.1. Physical characterization of spray dried omvPV
3.1.1. Particle size and morphology
A spray dried vaccine was prepared from OMVs of B. pertussis
(omvPV). The cumulative geometric mean (X50) particle size of powder
vaccine as determined by laser diffraction analysis was 5.1 ± 0.1 μm
(Table 1). No visible aggregates could be observed in the powders by
eye. Scanning electron micrographs (SEM) (Fig. 1A) revealed spherical
particles. Due to a preparation artifact some particles did stick to the
particles in the vicinity. SEM confirmed the results of the size mea-
surement by laser diffraction analysis.
3.1.2. Amorphous status of the spray dried formulation and residual
moisture content
Analysis of spray dried vaccine powder by DSC revealed a glass
transition temperature (Tg) of 73 ± 2 °C. The residual moisture content
of the spray dried omvPV was 2.3 ± 0.1% as determined by Karl
Fischer analysis. X-ray diffraction (XRD) was used to study the extent of
crystallinity. The expected peaks in the XRD profile indicated that solid
trehalose dihydrate (starting material) was crystalline. The absence of
peaks in the XRD profile of spray dried vaccine powder (Fig. 1B) in-
dicates that drying rendered an amorphous powder.
3.2. OmvPV stabilization during drying
The spray dried omvPV was reconstituted and then analyzed with
TEM (Fig. 2A) to evaluate whether the vesicle structure of omvPV was
preserved during the drying process. TEM analysis of liquid omvPV and
reconstituted powder omvPV revealed that spray drying did not affect
the particulate nature of omvPV. Both samples revealed an intact lipid
bilayer. The particle size of both products was found to be 100 to
150 nm. The particle size and structural integrity of both liquid and
reconstituted omvPV was also confirmed by DLS (Table 2). The average
size of omvPV particles (formulated with trehalose) was
129.7 ± 1.7 nm before and 133.3 ± 1.2 nm after drying, with a low
polydispersity index (0.22 ± 0.01). The particle size and morphology
were not affected by the drying process.
The total protein composition of the liquid omvPV and the recon-
stituted spray dried omvPV were analyzed using LC-MS and compared.
In total 195 proteins were identified and quantified in both samples. For
both samples, the top 25 most abundant proteins comprised 92% of the
total omvPV protein content Autotransporters Vag8 (50%) and BrkA
(21%) were the major antigens in both products. Furthermore, no ap-
parent differences were introduced by spray drying. (Supplementary
Fig. 1).
Since Vag8 is the most abundant protein present in omvPV [10], the
Vag8 antigenicity was determined by ELISA (Fig. 2B). Binding intensity
of an anti-Vag8 monoclonal antibody in the liquid omvPV and spray
dried omvPV was significantly better than the heat treated control (li-
quid omvPV sample stored at 65 °C), where nearly complete loss of
binding was observed. However, a 16% decrease in antibody binding
intensity was observed in the spray dried omvPV compared to the liquid
omvPV.
Pertactin (Prn) is a major antigen in the current aPV and was also
detected in abundance in omvPV (Supplementary Fig. 1). Therefore,
Prn antigenicity was also determined (Fig. 2C). No differences were
observed between spray dried and the liquid omvPV whereas heat
treated negative control (liquid omvPV stored at 65 °C) was sig-
nificantly less antigenic than both the liquid and spray dried omvPV.
To investigate changes in tertiary structure of proteins in the omvPV
after spray drying, intrinsic fluorescence (tryptophan residues) and
extrinsic fluorescence (Bis-ANS) were measured to determine the
changes in the environment of tryptophan [36] and the exposure of
hydrophobic sites [37], respectively. Liquid omvPV and reconstituted
spray dried omvPV showed similar emission spectra tryptophan
maxima, 339 ± 1 nm and 340 ± 1 nm, respectively, but with a de-
creased intensity for the spray dried product (Supplementary Fig. 2A).
For both products, the Bis-ANS maximum was 490 ± 2 nm with the
same intensity for both products (Supplementary Fig. 2B). The change
in tryptophan fluorescence indicated changes in protein tertiary struc-
ture due to spray drying. Since the analysis is on a protein mixture it is
unknown how many and which proteins are affected.
3.3. Thermostability of spray dried omvPV
To investigate the thermostability of the spray dried product, an
accelerated stability study (40 and 65 °C) was performed with liquid
and spray dried omvPV. Liquid omvPV (unformulated) stored at 2–8 °C
Table 1
Particle size of the spray dried pertussis outer membrane vesicles vaccine as
determined by laser diffraction using aspiros dispersing system.
Sample Particle size freshly prepared powder vaccine (μm)
X10 X50 X90
Spray dried omvPV 0.93 ± 0.02 5.09 ± 0.11 10.17 ± 0.02
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was used as a reference. The vesicle size in spray dried and liquid
omvPV was determined by DLS after storage. There was no change in
vesicle size of omvPV in liquid or spray dried product at 40 °C. No
change in vesicle size was noted at day 7 and 15 at 65 °C storage and on
day 30 an apparent increase in vesicle size (~163 nm) was observed for
spray dried omvPV (Supplementary Table 1). It is important to note
that the addition of trehalose in liquid omvPV formulation influenced
the vesicle size [formulated liquid omvPV (130 nm, Table 2) vs un-
formulated liquid omvPV (115 nm, Supplementary Table 1)].
The binding intensity of an anti-Vag8 monoclonal antibody to the
omvPV did not change for the liquid and spray dried omvPV after
prolonged storage at 40 °C (Fig. 3A). However, the binding decreased
by 80% in the liquid vaccine after 1 day at 65 °C, followed by complete
loss of antigenicity during further storage (Fig. 3A). On the other hand,
the Vag8 epitope was maintained in the spray dried omvPV during the
entire storage period.
To identify whether the epitope availability of other immunogenic
antigens was also affected by the applied storage conditions, SDS-PAGE
and Western blotting was performed on the liquid and spray dried
omvPV. When comparing the total protein composition in both spray
dried and liquid omvPV, a reduction in the intensity of an unknown
protein (20 kDa) due to spray drying was observed (Supplementary
Fig. 3). However, SDS-PAGE showed that the storage at 40 °C and 65 °C
had no further effect on both products. Subsequently, these samples
were analyzed in an immunoblot with a mixture of murine sera from
three omvPV-immunized groups (pulmonary liquid, pulmonary recon-
stituted powder and subcutaneous liquid). The antigenicity of the
omvPV components remained similar for both liquid and powder
omvPV stored at 4 °C and 40 °C (Fig. 3B). However, while the spray
dried omvPV stored at 65 °C remained stable, the liquid omvPV lost
antigenicity; epitopes on several antigens including Vag8 and BrkA next
to unknown proteins U1 and U2 disappeared after the heat treatment.
Several new bands were formed against unknown proteins U3, U4, and
U6 of respectively 38, 28 and 22 kDa, which may be degradation pro-
ducts. Not all antigens were affected, as the antibody binding to un-
known proteins U5, U7 and, as expected, LPS, remained intact.
To investigate changes in the tertiary structure of omvPV during
storage, both intrinsic and extrinsic fluorescence were analyzed. The
intensity of the tryptophan fluorescence of the liquid omvPV stored at
65 °C decreased by 306 F.I. units compared to the product stored at 4 °C
(Fig. 3C, i), whereas the spray dried omvPV only decreased by 114 F.I.
units (Fig. 3C, ii). The emission maximum for both products stored at
4 °C was 339 ± 2 nm. During storage at 65 °C, a shift of 8 nm was
observed for the liquid omvPV, whereas there was no shift in the
Fig. 1. - Physical characterization of omvPV powders. (A) Scanning electron micrographs (SEM). Powder morphology of spray dried omvPV. Scanning electron
micrographs of representative spray dried trehalose-stabilized omvPV. Magnification images left (100×) and right (5000×). (B) X-ray diffraction (XRD). The
patterns of spray dried vaccine samples in comparison with trehalose dihydrate (starting material). Trehalose dihydrate, the excipient (grey) is crystalline as depicted
by sharp peaks. In contrast to, spray dried omvPV (black) which was amorphous with no sharp peaks.
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emission maximum of the spray dried omvPV. Bis-ANS fluorescence
spectrum revealed an increased fluorescence intensity during elevated
temperature storage, for both liquid (125 F.I. units) (Fig. 3D, i) and
reconstituted spray dried (37 F.I. units) (Fig. 3D, ii) omvPV, indicating
protein unfolding during storage. Overall, storage at elevated tem-
peratures resulted in changes in the tertiary structure of both liquid and
spray dried omvPV, however these changes were more pronounced in
the liquid omvPV.
3.4. Immunogenicity of spray dried omvPV
3.4.1. Bacterial clearance from respiratory tract
In order to investigate the immunogenicity of the spray dried
omvPV, mice were immunized twice with a four week interval (day 0
and 28) by either pulmonary administration of liquid omvPV (PM-
mice), reconstituted omvPV powder (PMp-mice), or subcutaneous ad-
ministration of liquid omvPV (SC-mice) (Fig. 4). First, the efficacy of
the immunization was tested by investigating the number of colony-
forming units (cfu) in the lungs, trachea and nose of naive and im-
munized mice following a B. pertussis challenge, four weeks after the
second immunization (day 56) (Fig. 5). The cfu were determined in the
respiratory tract on day 1 and day 6 post-challenge. In lungs and tra-
chea of omvPV-immunized mice, no B. pertussis bacteria could be de-
tected, except for a few bacteria in the lungs of SC-mice, 1 day post
challenge, whereas naive mice were heavily colonized after a B. per-
tussis challenge (Fig. 5A and B). With respect to the nose, only PMp-
mice were free of viable B. pertussis bacteria, whereas the mice in other
groups showed presence of bacteria in the nasal wash. However, the
number of bacteria in the noses of PM- and SC-mice were lower com-
pared to naive mice (Fig. 5C). These results indicate that immunization
with omvPV does protect mice upon challenge. Moreover, spray drying
of the omvPV did not result in any loss in immunogenic efficacy.
3.4.2. IgA responses
To determine whether the (spray dried) omvPV induced mucosal
immune responses after pulmonary immunization, anti-OMV IgA-se-
creting cells, IgA-producing memory B-cells and IgA antibody responses
were assessed before challenge. Similar numbers of anti-OMV IgA-se-
creting cells were detected in the lungs, spleen and blood of both groups
that received pulmonary immunization while these numbers were sig-
nificantly higher than the numbers found in subcutaneously immunized
and naive control mice (Fig. 6A). With respect to IgA-producing
memory B-cells, significantly higher levels were observed in PM-mice
Fig. 2. - OmvPV stabilization during drying. (A) Morphology of omvPV particle. Cryo-transmission electron micrographs of omvPV before (left) and after (right)
spray drying and reconstitution. Magnification images A and B (80,000×). Arrows mark the lipid bilayer of the outer membrane vesicles. (B) Antigenicity of omvPV.
Vag8 epitope antibody binding ability as evaluated by ELISA. Green (liquid omvPV stored at 4 °C), blue (spray dried omvPV just after drying stored at 4 °C) and red
(negative control, omvPV stored for 1 day at 65 °C. Significant differences are indicated by * p < 0.05, ** p < 0.01, *** p < 0.001, obtained using a 2-way ANOVA,
NS=not significant. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Table 2
Vesicle size of the pertussis outer membrane vesicles as determined by dynamic
light scattering before and after spray drying.
Sample (n=3) Z-Ave (d.nm) PdI
Liquid omvPV (formulated with trehalose) 129.7 ± 1.7 0.22 ± 0.01
Reconstituted spray dried omvPV 133.3 ± 1.2 0.22 ± 0.01
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compared to the other groups. Despite the presence of IgA-producing
memory B-cells in the lungs of some PMp-mice, no significant differ-
ences were detected when compared to SC-mice or naive mice (Fig. 6B).
Moreover, there were no significant differences detected between the
groups in the levels of anti-OMV IgA-producing memory B-cells in the
spleen (Fig. 6B). In accordance with the findings on IgA producing B-
cells, IgA antibodies were exclusively detected in PM-mice and PMp-
mice, in lungs (Fig. 6C), nose (Fig. 6E) and serum (Supplementary
Fig. 4A). In lungs of PM-mice, IgA antibodies were found to be directed
against BrkA, FHA, Fim2/3, Prn, Ptx, OMV and Vag8. With the excep-
tion for anti-FHA, these levels were all significantly higher in PM mice
when compared to PMp-mice (Fig. 6C). The anti-OMV IgA detected in
the lungs of PM-mice and PMp-mice was clearly directed against the
vaccine constituents Vag8 and LPS (Fig. 6D). In the nose lavages of all
pulmonary immunized mice, IgA antibodies directed against all mea-
sured antigens were found significantly enhanced compared to naive
and SC-mice (Fig. 6E). The levels of anti-Ptx and anti-Prn IgA were
significantly higher in PM-mice compared to PMp-mice. In SC-mice, a
small detectable amount of anti-OMV IgA was observed (Fig. 6E). In
serum, only a modest induction of IgA antibodies directed against OMV
was found in both pulmonary immunized groups and for PM-mice also
against Prn compared to naive and SC-mice (Supplementary Fig. 3A). In
addition, both pulmonary immunized groups exhibited increased levels
of anti-Vag8 IgA in the serum compared to naive mice. Thus, mucosal
IgA-related responses were almost solely induced after pulmonary im-
munization of omvPV.
3.4.3. IgG responses
To determine whether the spray dried omvPV was capable of in-
ducing systemic immune responses after pulmonary immunization,
anti-OMV IgG-secreting cells, IgG-producing memory B-cells and IgG
(subclass) antibody responses were determined. Significantly increased
numbers of OMV-specific IgG plasma cells were detected in spleen,
lungs and blood of all omvPV-immunized mice compared to naive mice,
Fig. 3. - Storage stability of omvPV. (A) Antigenicity of omvPV on storage at elevated temperatures (40 °C and 65 °C). Effect of temperature on Vag8 epitope antibody
binding ability as evaluated by ELISA. (B) Western Blot showing the epitope availability of immunogenic antigens present in liquid and spray dried omvPV stored at
4 °C, 40 °C and 65 °C. (C) Intrinsic Fluorescence; the effect of storage at 65 °C for 4 weeks on tryptophan fluorescence. i) Fluorescence emission spectra of liquid
omvPV. ii) Fluorescence emission spectra of reconstituted spray dried omvPV. (D) Extrinsic Fluorescence; the effect of storage at 65 °C for 4 weeks on Bis-ANS
fluorescence. i) Fluorescence emission spectra of liquid omvPV. ii) Fluorescence emission spectra of reconstituted spray dried omvPV.
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7 days after booster immunization (Fig. 7A). In the spleen, numbers of
plasma cells were significantly lower in PMp-mice when compared to
SC-mice. On the other hand, significantly higher numbers of these
plasma cells were observed in the lungs of both mucosally immunized
groups compared to the SC-mice. In the blood, no significant differences
were observed between the immunized groups (Fig. 7A). Increased
numbers of OMV-specific IgG memory B-cells were found in the spleens
of all immunized mice (Fig. 7B). In the lungs, numbers of IgG memory
B-cells were significantly enhanced in both groups receiving pulmonary
immunization compared to naive mice. Moreover, the PM-mice de-
monstrated significantly higher numbers of IgG memory B-cells in the
lungs compared to both PMp- and SC-mice (Fig. 7B).
In serum, the levels of IgG antibodies directed against BrkA, FHA,
Prn, OMV, and Vag8 were significantly enhanced in the omvPV-im-
munized groups compared to naive mice (Fig. 7C). Anti-Prn IgG levels
were significantly lower in PMp-mice compared to PM- and SC-mice.
Moreover, the levels of IgG antibodies directed against BrkA, FHA and
Vag8 were slightly higher in SC-mice compared to mice receiving pul-
monary immunization (Fig. 7C). The immunoproteomic profile of
serum IgG revealed no differences between both PM- and PMp-mice,
whereas the SC-mice induced additional antibodies against a few other
antigens such as GroEL (Fig. 7D). All omvPV-immunized mice demon-
strated the induction of a broad IgG subclass response as all mice in-
duced significant levels of IgG1, IgG2a, IgG2b and IgG3 antibodies
against a variety of antigens compared to naive mice (Supplementary
Fig. 4B). Of note, the anti-Prn IgG1 and IgG2b levels were significantly
lower in PMp-mice when compared to PM- and SC-mice. IgG3 levels
were slightly higher in SC-mice when compared to pulmonary im-
munized mice, especially PM-mice.
These results indicate that IgG immune responses were induced by
omvPV immunization irrespective of the route of administration.
However, compared to non-spray dried material, immunization with
spray dried omvPV resulted in lower numbers of IgG-producing
memory cells in the lungs and lower levels of serum antibodies against
Prn. This may indicate an effect due to spray drying.
3.4.4. T-cell responses
To determine the effect of omvPV immunization on T-cell responses,
Fig. 4. - Immunization study design. BALB/c mice were immunized twice (day 0 and day 28) with liquid omvPV via pulmonary (PM; red) or subcutaneous (SC; blue)
administration or reconstituted powder via pulmonary administration (PMp; yellow). A B. pertussis challenge (2×105 cfu) was performed on day 56 in both
vaccinated groups and naive mice (green). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 5. - B. pertussis colonization in the respiratory tract. Naive and vaccinated mice were challenged with B. pertussis (2× 105 cfu) on day 56 and the number of
colony-forming units (cfu) were subsequently determined on day 57 and 62 in (A) lungs, (B) trachea, and (C) nose lavages. Significant differences are indicated by *
p < 0.05, ** p < 0.01, *** p < 0.001 obtained using a t-test after log-transformation of data.
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levels of seven T-cell related cytokines in supernatants of OMV-stimu-
lated splenocytes and lung cells were analyzed. The presence of IFNγ
and IL-17A, indicative for Th1 and Th17 responses, respectively, was
observed in the supernatant of OMV-stimulated splenocytes for all ad-
ministration routes. As expected, the IL-17A response was higher in the
mice receiving mucosal administration (Fig. 8A). IL-10 levels were in-
creased in all immunized groups. Levels of IL-4 and IL-13, indicative of
a Th2 response, were enhanced in all immunized groups but were
slightly higher in SC-mice. A significantly higher IL-5 production (also a
Th2 marker) was observed in all omvPV-immunized mice, but these
levels were more pronounced for the subcutaneous administration
compared to the mucosal administration.
Stimulation of lungs cells with OMVs led to increased levels of IFNγ
(Th1) and IL-17A (Th17) in all immunized groups, but these levels were
significantly higher in both mucosal administrated groups compared to
the subcutaneously administrated group (Fig. 8B). Furthermore, the
IFNγ and IL-17A levels were significantly higher in the mice receiving
the liquid omvPV compared to the ones receiving the reconstituted
spray dried omvPV. IL-10 and IL-13 were induced in the lung cell
cultures of mice receiving mucosal administration compared to the
mice receiving subcutaneous administration and the naive mice. IL-5
production was solely observed in the lung cell cultures of mice that
received the liquid omvPV after pulmonary immunization. The IL-4
production was significantly higher after subcutaneous administration
compared to the pulmonary administration and the naive mice. In
conclusion, omvPV induced a broad immune response, regardless of the
administration route. However, the balance changed towards a stronger
Th17 profile upon pulmonary administration.
4. Discussion
The present study reports the development of a novel spray dried
pertussis vaccine formulation, based on OMVs, with increased ther-
mostability compared to the liquid formulation. Results show that spray
dried omvPV could be prepared without aggregation or decomposition
of the vesicles. Although a decrease in Vag8 antigenicity after drying
suggested minor epitope loss. However, when administered via the
pulmonary route after reconstitution, the spray dried omvPV exhibited
comparable immune responses as well as similar protection (upon
challenge with live bacteria) as compared to the liquid vaccine when
administered via the same route. Moreover, in contrast to the liquid
omvPV the Vag8 antigenicity of the spray dried omvPV was maintained
Fig. 6. - Mucosal humoral responses. (A-B) Numbers of (A) OMV-specific IgA-secreting plasma cells in lungs, blood, and spleens and (B) numbers of IgA-producing
memory cells in spleens and lungs were determined by B-cell ELISpot of 6 mice per group at day 35 and day 56, respectively. Results are indicated as antibody-
secreting cells (ASCs) per 5× 105 cells. (C-E) Levels of immunoglobulin A (IgA) antibodies directed against Ptx, Prn, FHA, Fim2/3, BrkA, Vag8 and OMV were
determined in (C) the lungs and (E) the nose. Results are expressed as fluorescence intensities (F.I.) of 6 mice per group. (D) Immunoproteomic profile of pooled
(n=6) pulmonary IgA was determined using Western blotting. Significant differences are indicated by * p < 0.05, ** p < 0.01, *** p < 0.001 obtained using a
Mann-Whitney t-test (B-cells) and t-test (antibodies) after log-transformation of data.
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during storage at 65 °C for 4 weeks as depicted by the antibody binding
assays, providing a promising prospect for the design of a more stable
solid vaccine dosage form.
Not much is known about spray dried OMVs. Arigita et al. [38]
reported the use of freeze drying for an OMV of Neisseria meningitidis in
the presence of sucrose (3% w/v), but this resulted in aggregation
possibly due to rupture of the vesicular structure during the freezing
step. Much more is known on drying of liposomes. Although there are
many differences between liposomes and OMVs, some physical and
biochemical aspects are similar. Ohtake et al. [39] successfully used
trehalose for stabilization of DPPC-cholesterol vesicles during freeze
drying. Trehalose (5% w/v) provided stability to the phospholipid
membrane by direct interaction with it, possibly due to hydrogen
bonding. In the current study, spray drying of omvPV using trehalose
(10% w/v) preserved the vesicular structure of the vaccine (as observed
by DLS and TEM), further no aggregation occurred (as concluded from
DLS data). Trehalose is believed to exert its protective mechanism by
immobilization of the vaccine in an amorphous matrix portrayed by the
vitrification theory [40]. Thus, based on the ability of trehalose to in-
teract with protein surfaces [41], it proved to be a good choice for
stabilizing omvPV.
Storage at elevated temperatures, but also the spray drying process
itself may affect the conformation of antigens, thereby resulting in a
change in antigenicity [42] and possibly as a result the im-
munogenicity. Spray drying of omvPV revealed some changes in the
tertiary structure as shown by changes in protein fluorescence intensity.
As omvPV contains many proteins, we cannot say which proteins and
how many were affected. Therefore, the antigenicity of two important
antigens was followed using one monoclonal antibody per antigen:
Vag8 and Prn. Spray drying moderately affected Vag8 antigenicity
while Prn was not affected. Storage of vaccine in liquid or powder form
at 40 °C for 30 days did not affect the epitope binding profile as shown
by Western blot and Vag8 ELISA. Apparently, storage at 40 °C for the
specified time period was not sufficient to induce changes in anti-
genicity of the investigated epitopes. However, storage at 65 °C resulted
in a significant change of the epitope binding profile and loss of Vag8
and BrkA antigenicity in the liquid omvPV. These are two major anti-
gens of omvPV and are likely important for contribution to an effective
neutralization of B. pertussis [43–45]. Thus, this is a clear indication
that after elevated storage temperature the liquid formulation will re-
sult in inferior protective immunity compared to the spray dried for-
mulation. In contrast, incubation of spray dried omvPV at 65 °C did not
show any changes in antigenicity. While the vesicle remained non-ag-
gregated during storage for both products, changes in tertiary structure
were more pronounced in the liquid omvPV compared to the spray
dried omvPV indicating enhanced storage stability of omvPV after
drying.
An immunization study demonstrated immunogenicity and protec-
tive capacity of the omvPV after spray drying. In comparison to the
liquid omvPV, the spray-dried omvPV maintained its capability to in-
duce strong and broad IgG antibody responses [10, 46], systemic
plasma and memory B-cells [13] and a mixed systemic Th1 and Th17
response [10, 12–14]. Moreover, mucosal immunity was attained by
pulmonary administration [13], given the significant amounts of IgA
plasma and memory B-cells, pulmonary and nasal IgA responses and
Th17 responses in the lungs. Pulmonary administration of spray dried
omvPV provided protection against Bordetella pertussis in a similar
manner as the liquid omvPV in our mouse challenge model. These
mucosal responses and improved level of protection induced by pul-
monary omvPV immunization were comparable with infection-induced
responses by B. pertussis [13, 15, 16, 34]. Moreover, the protection was
similar to subcutaneously administered vaccine. This indicates that
spray drying, despite antigenic changes, did not affect vital components
of the vaccine that are required for obtaining immunity.
A few differences in antibody profiles were observed, that were
perhaps due to spray drying. The spray dried omvPV evoked lower
Fig. 7. - Systemic humoral responses. (A-B) Numbers of (A) OMV-specific IgG-secreting plasma cells in lungs, blood, and spleens and (B) numbers of IgG-producing
memory cells in spleens and lungs were determined by B-cell ELISpot of 6 mice per group at day 35 and day 56, respectively. Results are indicated as antibody-
secreting cells (ASCs) per 5× 105 cells. (C) Levels of immunoglobulin G (IgG) antibodies directed against Ptx, Prn, FHA, Fim2/3, BrkA, Vag8 and OMV were
determined in serum. Results are expressed as fluorescence intensities (F.I.) of 6 mice per group. (D) Immunoproteomic profile of pooled (n= 6) serum IgG was
determined using Western blotting. Significant differences are indicated by * p < 0.05, ** p < 0.01, *** p < 0.001 and were obtained by using a Mann-Whitney t-
test (B-cells) and t-test (antibodies) after log-transformation of data.
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number of pulmonary IgG- and IgA memory B-cells as well as lower
levels of pulmonary IgA antibodies against BrkA, Fim, OMV, Prn, Ptx
and Vag8. As the nasal IgA antibody responses against these antigens
were not affected, this seems not an effect due to spray drying but a
possible effect of the distribution in the respiratory tract. Pertactin did
seem to be slightly affected by spray drying. However, no change in
epitope availability was demonstrated during product characterization
with a Prn-specific monoclonal antibody, the in vivo systemic anti-Prn
IgG antibody induction was lower. On the contrary, the product char-
acterization did demonstrate a moderately affected Vag8 antigenicity
after drying. However, this effect did not result in an altered anti-Vag8
antibody response. Of note, the in vivo-induced polyclonal antibodies
cover a broader range of epitopes on antigens as compared to the in-
cluded monoclonal antibodies used in vitro.
In the current study, we demonstrated that the administration of
reconstituted spray dried omvPV powder induced protective immune
responses in a mouse challenge model [13]. At this point, the delivery
with either reconstituted or powder would most likely give a similar
indication whether changes have occurred during drying. Direct
inhalation of the spray dried powder itself could even enhance better
dispersion in the respiratory tract and circumvent the logistics of re-
constitution [42]. However, Tonnis et al. [47] have previously shown
that the Penn-Century dry powder insufflator, deposits spray dried
powder (X50 4.5 μm) predominantly in the trachea of mice, leaving a
relatively small amount of powder to reach the lungs. Moreover, spray
dried trehalose is hygroscopic and would likely agglomerate in the
device so such an approach would require further formulation studies
to mitigate that. In a clinical situation where the vaccine is adminis-
tered to humans, devices like Twincer® can be used for pulmonary
delivery of spray dried powders [48]. A study from Saluja et al. [49]
showed that agglomeration of spray dried powders and their retention
in the delivery devices like Twincer® can be reduced by addition of so
called sweeper crystals like mannitol. Further work is required to es-
tablish the pulmonary delivery of pertussis vaccine as a powder, pre-
ferably in more suitable animals like baboons [50] or even in clinical
studies.
In conclusion, the study demonstrates that spray drying can be used
to produce an omvPV powder. The powder has an improved stability at
Fig. 8. - Cytokine levels in supernatants of OMV-stimulated splenocytes and lung cells. (A-B) The presence of cytokines in day 3 culture supernatants of (A)
splenocytes and (B) lung cells collected on day 56 was tested using a multiplex assay. Results are corrected for the background level (medium control) and are given
as mean ± SD of 6 mice per group. Significant differences are indicated by *p < 0.05, ** p < 0.01, *** p < 0.001 obtained using a t-test after log-transformation
of data.
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increased temperatures compared to the liquid formulation. Despite
small changes in antigenicity during drying, when pulmonary im-
munized in mice, the immunogenicity and protection induced by re-
constituted spray dried omvPV was very similar to the responses in-
duced by the liquid omvPV. Thus, the spray drying of omvPV could
facilitates extended storage outside the cold chain and is a promising
technology for future powder immunization.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jconrel.2018.07.035.
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